Interval Between Colonoscopies May Be Lengthened For Some Colorectal Cancer Patients, Ochsner Study Concludes

Publication
Article
OncologyONCOLOGY Vol 10 No 8
Volume 10
Issue 8

The interval between follow-up colonoscopies may be increased from 1 to 3 years for colorectal cancer patients whose examinations are negative after 2 years, concludes a study of 389 patients at the Ochsner Clinic, New Orleans, Louisianna,

The interval between follow-up colonoscopies may be increasedfrom 1 to 3 years for colorectal cancer patients whose examinationsare negative after 2 years, concludes a study of 389 patientsat the Ochsner Clinic, New Orleans, Louisianna, reported inDiseases of the Colon & Rectum (DC&R).

"We believe this recommendation outlines appropriate andcost-effective colon surveillance guidelines for colorectal cancerpatients and will help decrease the total number of normal surveillanceexaminations," write Ochnser's Douglas A. Khoury, MD, FrankG. Opelka, MD, David E. Beck, MD, Terry C. Hicks, MD, Alan E.Timmcke, MD, and J. Byron Gathright, Jr., MD.

Current guidelines of the American Society of Colon and RectalSurgeons (ASCRS) recommend annual colonoscopies for up to 5 yearsafter a patient has surgery for colorectal cancer.

Reoperation Plus Surgery for Local Recurrence of Recal Carcinoma

Another study reported in the March issue of DC&R offers increasedhope for patients who experience a local recurrence of cancerafter surgery for rectal cancer. "In selected patients withlocal recurrence of rectal carcinoma, reoperation with irradiationmay result in good palliation and possibly cure," reportTheoWiggers, MD, PhD, Mark R. de Vries, MD, and Bernadette Veeze-Kuypers,MD, of the Departments of Surgical Oncology and Radiotherapy atDr. Daniël den Hoed Cancer Center in Rotterdam, The Netherlands.

Surgery is the most effective treatment for colorectal cancer.Even when all visible cancer has been removed, it is possiblefor cancer cells to be present in other areas of the body. Thechance of recurrence depends on the characteristics of the originalcancer and the effectiveness of chemotherapy or radiation, ifneeded, or other follow-up treatment. Patients with recurrentcancers--if diagnosed early--may benefit, or be cured, by furthersurgery or other treatment.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content